Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RotaTeq

- PMLiVE

Trial backs role for Lynparza in second-line prostate cancer

Demonstrates potential significant benefit in treatment of disease

- PMLiVE

Hal Barron touts new drive to improve GSK’s research output

'Consensus-led' research being replaced with bold decision-making

- PMLiVE

ViiV builds case for switching to its two-drug HIV combinations

Taking aim at rival Biktarvy

- PMLiVE

Merck says it has plenty in the pipe beyond Keytruda

It has the firepower, but is Merck seeking a big deal?

- PMLiVE

Merck & Co adds to immunotherapy again with $773m Tilos buy

Specialises in TGFβ complex-targeting therapies

- PMLiVE

McCann’s Breath of Life diagnostic wins Cannes Lion prize

Grand Prix awarded for first time in three years

- PMLiVE

GSK joins forces with Doudna’s CRISPR lab

New recruit Chris Miller will head GSK's functional genomics push

- PMLiVE

GSK’s Nucala gets boost with self-administration approval

Fasenra and Dupixent pose threat to leader

- PMLiVE

AZ reports stellar results for Lynparza in pancreatic cancer

Plans to file as soon as possible

- PMLiVE

Merck bulks up in cancer with $2.2bn Peloton buy

Another significant bolt-on in oncology

Infographic: The vaccine opportunity in Asia

Asia is home to 60% of the world’s population and is one of the fastest growing vaccine markets in the world. A rising demand for better healthcare infrastructure and high...

Research Partnership

- PMLiVE

Shingrix lifts GSK in Q1, but two more vaccines are culled

Synflorix follow-up and influenza vaccine fail to make the cut

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links